Targeted Oncology· @TargetedOnc · X·· 1 天前评分70
正文 · 原文
Live from #ESMO26 Madrid with @TargetedOnc!
Today: KEYNOTE-B49, COMPANION-002, DUO-E, NRG-GY020, INTerpath-001, VOLGA, DeLLphi-305 & DASL-HiCaP.
We’ll discuss the results, clinical implications & what could truly change practice. Join us!
64 浏览 · 0 赞 · 1 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com